Epcoritamab

Epcoritamab (Epkinly in the US, Tepkinly in Europe) is a subcutaneous CD3xCD20 bispecific antibody from Genmab and AbbVie, FDA-approved in May 2023 for relapsed/refractory diffuse large B-cell lymphoma after two or more prior therapies [1]. NCT05578976 (EPCORE DLBCL-2) is a Phase 3 label-expansion study moving the drug into frontline DLBCL by adding it to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the standard chemo-immunotherapy backbone newly diagnosed DLBCL patients have received for the past twenty years) [2]. If the trial beats R-CHOP on progression-free survival, epcoritamab shifts from a late-line salvage option into a drug that touches most newly diagnosed DLBCL patients, a US market of roughly 25,000 cases per year. The competitive setup is tight: Roche's bispecifics glofitamab and mosunetuzumab are chasing identical frontline expansions, and Roche's polatuzumab vedotin (an anti-CD79b antibody-drug conjugate, not a CD3xCD20 bispecific) already raised the frontline bar with Pola-R-CHP in 2023 [3]. The scientific question is not whether CD3xCD20 engagement works. That question got answered in R/R DLBCL and follicular lymphoma. The question is whether stacking a T-cell engager on top of chemotherapy adds enough clean efficacy to justify the toxicity cost in previously untreated patients who already have a 60-70% cure rate on standard therapy.

Epcoritamab is an approved drug being studied for a new indication, not a novel compound. The approved indication is R/R DLBCL after two or more lines, granted accelerated approval (an FDA pathway that allows earlier approval based on a surrogate endpoint like overall response rate, conditional on a required confirmatory trial to verify clinical benefit) under BLA761324 on May 19, 2023, based on overall response rate and duration of response from EPCORE NHL-1 [1][4]. The accelerated approval carries a confirmatory trial obligation that sits on a separate Phase 3 (EPCORE DLBCL-1 monotherapy vs. investigator choice in R/R DLBCL), not the frontline trial covered here. If that confirmatory readout fails to verify benefit, FDA retains authority to withdraw the current R/R DLBCL label, so the marketed franchise is not fully derisked even though the drug is on the market. Expansion into follicular lymphoma has progressed through EPCORE NHL-2 (frontline FL with rituximab plus lenalidomide, phase 1/2b) [5] and the pivotal FL registration program, with recent data confirming deep responses measured by circulating tumor DNA and peripheral blood MRD [6]. NCT05578976 (EPCORE DLBCL-2) is Phase 3, actively enrolling, with Genmab as trial sponsor and AbbVie as commercialization partner. No FDA designations have been publicly disclosed specific to the frontline DLBCL indication. Readout timing has not been guided to a specific quarter, and because frontline DLBCL regimens have long PFS tails, event-driven analysis likely pushes meaningful data to 2027 or later. Approval in frontline would convert the current accelerated-approval posture in R/R into a durable franchise and position epcoritamab against Roche's parallel bispecific programs in the race for first-line real estate.

Epcoritamab binds two things at once. One arm grabs CD20, a protein stuck on the surface of B cells, including the malignant B cells that drive DLBCL and follicular lymphoma. The other arm grabs CD3, part of the signaling machinery on T cells. By tethering a T cell directly to a cancerous B cell, epcoritamab forces the T cell to kill the B cell, bypassing the normal requirement that a T cell recognize a specific tumor antigen through its own receptor [7]. Think of it as a physical zip tie between the hitman and the target. Mechanism validation is strong on three independent axes. First, rituximab (anti-CD20 alone) has been standard of care for B-cell lymphoma for 25 years, so CD20 is a dependable address on these tumors. Second, blinatumomab validated CD3-engaging bispecifics in B-ALL. Third, within the CD3xCD20 class specifically, both glofitamab (FDA-approved for R/R DLBCL in 2023) and mosunetuzumab (approved for R/R FL in 2022) have shown response rates above 50% in heavily pretreated lymphoma, giving two approved class members as class-level derisking for the CD3xCD20 mechanism. One differentiator: epcoritamab is subcutaneous rather than IV, which matters for infusion-chair capacity and community-practice adoption. The mechanism is well-grounded. The open question is dose and sequencing when combined with cytotoxic chemotherapy.

NCT05578976 is a Phase 3 open-label randomized trial of epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed DLBCL [2]. Primary endpoint is progression-free survival, consistent with FDA precedent in frontline DLBCL (POLARIX used PFS). Secondary endpoints include complete response rate, event-free survival, and overall survival. Enrollment target has been in the range of roughly 900 patients globally based on sponsor communications, with the trial active and not yet closed to accrual. Design strengths: large size with adequate power, randomized against a globally accepted comparator, PFS primary with OS as a key secondary. Design concerns: R-CHOP alone is the comparator, but Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) was approved in April 2023 after beating R-CHOP in POLARIX [3], so the real-world standard of care is shifting away from pure R-CHOP in many markets. A trial that beats R-CHOP but has not been tested head-to-head against Pola-R-CHP faces a tougher clinical adoption case even with regulatory approval. Step-up dosing to mitigate cytokine release syndrome is built into the protocol, informed by exposure-response modeling and repeated time-to-event analysis of CRS risk [8][9]. Enrollment pace matters: Roche's SKYGLO trial (NCT06047080, glofitamab plus Pola-R-CHP vs. Pola-R-CHP in previously untreated large B-cell lymphoma, roughly 1,130 patients) is pulling from the same patient pool [12].

Epcoritamab is FDA-approved (EPKINLY, 2023-05-19). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

Efficacy risk centers on whether CD3xCD20 engagement adds enough to R-CHOP's roughly 60-70% cure rate to produce a statistically clean PFS delta. The frontline DLBCL floor is high. POLARIX delivered a 6.5% absolute PFS improvement with Pola-R-CHP, which was enough for approval but modest, and that gives a reference for how little margin exists at the top of the response curve [3]. Safety risk is specific and documented: cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome carry black-box warnings on the current Epkinly label [1]. The public FDA FAERS dashboard shows cumulative post-approval reports in the low thousands, with the majority classified serious and CRS and ICANS as the dominant signals; these figures are directional reads from the public dashboard rather than a timestamped audited pull, and specific case counts should be verified against FAERS directly if the number is load-bearing to a decision [10]. Combining a T-cell engager with cytotoxic chemotherapy stacks neutropenia and infection risk, with cytomegalovirus reactivation already appearing as a monotherapy signal in post-marketing reports. Execution risk includes direct enrollment competition from Roche's parallel Phase 3 bispecific programs in frontline DLBCL. Regulatory risk reaches beyond the frontline trial itself: because the R/R DLBCL label is an accelerated approval, a failure in the ongoing confirmatory Phase 3 (EPCORE DLBCL-1 monotherapy in R/R DLBCL) could trigger withdrawal of the marketed label, which would damage the frontline opportunity by removing the drug's established commercial anchor. Commercial risk: payers and oncologists may demand superiority over Pola-R-CHP, not just R-CHOP. Even an approval does not guarantee community uptake if the CRS monitoring requirements keep step-up dosing anchored at specialty centers rather than community infusion suites.

Worth watching, high stakes. Epkinly is already a commercial product: Genmab reported 2024 global net sales of approximately $131M for Epkinly/Tepkinly, up 45% year-over-year from $90M in 2023, with Genmab receiving tiered royalties of 22-26% on net sales outside the US and Japan under the AbbVie collaboration [11]. Frontline DLBCL is where the long-dated franchise value lives. The signal to watch is the interim PFS analysis for EPCORE DLBCL-2 alongside Roche's SKYGLO readout (glofitamab plus Pola-R-CHP in frontline large B-cell lymphoma, NCT06047080) [12]. If epcoritamab delivers a PFS hazard ratio (the ratio of event rates between arms, where values below 1 favor the experimental arm and roughly 0.7 or lower is typically considered clinically meaningful in frontline DLBCL) in the 0.6 to 0.7 range against R-CHOP, it secures its place in the frontline. If the delta is thinner, or if SKYGLO reads out first with a cleaner hazard ratio, the commercial case erodes quickly. The third CD3xCD20 entrant to track is odronextamab (Regeneron): it earned EU approval as Ordspono in R/R FL and R/R DLBCL in August 2024, but received an FDA complete response letter in March 2024 citing enrollment status in confirmatory trials (not efficacy or safety), with a resubmission for R/R FL under FDA review in 2025 [13]. On AbbVie's side, 2024 full-year net revenues were $56.3B [14], so Epkinly is currently a sub-1% revenue contributor; accretive but not transformative. For Genmab the equation is different: royalty economics on Epkinly make it one of their two commercial anchors alongside daratumumab, and a frontline label meaningfully extends the duration of their royalty stream. Franchise longevity is backstopped by 12-year FDA biologics reference-product exclusivity, which runs through May 2035 from the May 2023 BLA approval; composition-of-matter patent coverage is estimated to extend into the early-to-mid 2030s, with potential patent term extension pushing the cliff later but not verified here. Check back on the Q2 and Q3 2026 earnings calls from both companies for enrollment and interim timing commentary, and watch the ASH 2026 and 2027 abstract books for the first look. The structural audit flag on this node (approved molecule being tracked as pipeline-scope) is worth keeping in mind: the drug itself is derisked at the molecule level, the frontline indication is not.